Abdominal Aortic Aneurysm (AAA) is typically a disease of older males with increasing prevalence after the 6th decade of life and an incidence of 6.5 per thousand person years. 10% of the population older than 65years presents an AAA.
The endovascular aneurysm repair (EVAR) is considered nowadays the mainstay treatment of AAA compared to open repair due to its minimal invasive nature and its lower perioperative mortality and morbidity. The fundamental philosophy of the stent-graft technology is focused on the exertion of a radial force continuously applied by a Nitinol skeleton, over-sized with regard to the diameter of the healthy infrarenal aortic segment. This sealing technology, often coupled with suprarenal fixation mechanisms, carries certain limitations with respect to minimum anatomical requirements of angulation, diameter and length of the infrarenal and iliac sealing zones.
The sealing and fixation mechanisms, the accuracy of deployment and the profile of the delivery devices have evolved rapidly over the last decade with newer endografts recruited to widen the eligibility for EVAR at no cost to safety and efficacy. Moreover, sophisticated and technically demanding endovascular techniques (branched-, fenestrated- or chimney EVAR) were developed to manage pararenal, juxtarenal and thoracoabdominal AAA, while modified designs were introduced to address simultaneously the presence of iliac aneurysms accompanying AAA. However, despite the initial enthusiasm, certain queries remain still unanswered, such as the mid- and long-term clinical success of the newer endografts, the competitive efficacy of fenestrated- and chimney EVAR in the treatment of complex AAA and the management of technical failures of the new endograft designs.
Aim of this issue is to present the current status of endovascular treatment of AAA, describe the technical improvements and modifications of previous and newer endograft designs, compare the critical issues related to the advanced treatment modes of complex AAA and address the challenges to treatment of failures of the new endograft designs.
Prof. Dr. Efstratios Georgakarakos
Manuscripts should be submitted via our online editorial system at https://jour.ipublishment.com/imr/access/login by registering and logging in to this website. Once you are registered, click here to start your submission Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted papers should be well formatted and use good English.